Viking TherapeuticsLTS:0VQA +6.74%29 Interest Coverage is No Debt (1) as of Mar. 2026. GuruFocus rates LTS:0VQA with a GF Score™ of 29/100. The stock has 3 warning signs investors should review. Among 376 Biotechnology companies, Viking Therapeutics ranks worse than 265957.18% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Viking Therapeutics's
Operating Income
for the
three
months ended in Mar. 2026 was $-164.13 Mil. Viking Therapeutics's Interest Expense for the
three
months ended in Mar. 2026 was $0.00 Mil.
Viking Therapeutics has no debt.
The higher the ratio, the stronger the company's financial strength is.
(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Viking Therapeutics's Interest Coverage or its related term are showing as below:
LTS:0VQA's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 110.86 * Ranked among companies with meaningful Interest Coverage only.
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Viking Therapeutics Interest Coverage Related Terms
Viking Therapeutics Interest Coverage Historical Data
* Premium members only.
The historical data trend for Viking Therapeutics's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
LTS:0VQA vs EWTX, ACAD, DNLI: Interest Coverage Comparison
For the Biotechnology subindustry, Viking Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viking Therapeutics Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viking Therapeutics's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Viking Therapeutics's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of No Debt <sup>(1)</sup> mean?
Viking Therapeutics (LTS:0VQA) has a Interest Coverage of No Debt (1) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Viking Therapeutics and its competitors. According to the industry distribution chart, Viking Therapeutics ranks #999999 out of 376 companies in the Biotechnology industry.
Is Viking Therapeutics' Interest Coverage too high?
Viking Therapeutics' current Interest Coverage is No Debt (1). Based on the distribution chart, Viking Therapeutics ranks #999999 out of 376 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Viking Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Viking Therapeutics' Interest Coverage compare to EWTX and ACAD?
According to the Biotechnology industry distribution chart, Viking Therapeutics ranks #999999 out of 376 companies for Interest Coverage. This places Viking Therapeutics in the lower half of its industry. The industry median Interest Coverage is 110.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 110.86, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Viking Therapeutics and its competitors. For the Biotechnology industry, the median Interest Coverage is 110.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viking Therapeutics's current Interest Coverage is No Debt (1). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viking Therapeutics stock overvalued right now?
Viking Therapeutics (LTS:0VQA) has a current Interest Coverage of No Debt (1). The current Interest Coverage is No Debt (1). Viking Therapeutics' overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Viking Therapeutics (LTS:0VQA), the current Interest Coverage is No Debt (1) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
29GF Score
Get the complete analysis for LTS:0VQA
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0VQA has been successfully added to your 
